Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
PTCT [NASD]
PTC Therapeutics, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-5.62 Insider Own0.20% Shs Outstand70.42M Perf Week-4.56%
Market Cap2.92B Forward P/E- EPS next Y-4.32 Insider Trans-11.08% Shs Float68.50M Perf Month3.47%
Income-391.10M PEG- EPS next Q-1.43 Inst Own- Short Float6.57% Perf Quarter-8.21%
Sales471.90M P/S6.18 EPS this Y-55.30% Inst Trans-0.23% Short Ratio11.52 Perf Half Y-26.88%
Book/sh2.79 P/B14.55 EPS next Y36.80% ROA-18.30% Target Price57.80 Perf Year-13.31%
Cash/sh13.18 P/C3.08 EPS next 5Y-9.51% ROE-105.50% 52W Range36.38 - 70.82 Perf YTD-33.49%
Dividend- P/FCF- EPS past 5Y-5.50% ROI-31.20% 52W High-42.69% Beta1.16
Dividend %- Quick Ratio3.60 Sales past 5Y59.60% Gross Margin94.50% 52W Low11.57% ATR1.33
Employees967 Current Ratio3.70 Sales Q/Q55.20% Oper. Margin-73.80% RSI (14)44.75 Volatility3.08% 3.43%
OptionableYes Debt/Eq5.91 EPS Q/Q39.60% Profit Margin-82.90% Rel Volume0.70 Prev Close40.56
ShortableYes LT Debt/Eq5.67 EarningsJul 29 AMC Payout- Avg Volume390.98K Price40.59
Recom2.50 SMA20-1.96% SMA50-1.30% SMA200-18.68% Volume287,677 Change0.07%
Apr-26-21Resumed Credit Suisse Neutral $54
Mar-29-21Upgrade RBC Capital Mkts Underperform → Sector Perform $47
Feb-12-21Downgrade BofA Securities Buy → Neutral
Jan-05-21Upgrade Citigroup Neutral → Buy $67 → $85
Nov-30-20Downgrade RBC Capital Mkts Sector Perform → Underperform $45
Oct-30-20Downgrade Citigroup Buy → Neutral
Oct-28-20Initiated UBS Neutral $55
Oct-07-20Upgrade JP Morgan Neutral → Overweight $71
Aug-25-20Initiated Raymond James Outperform $63
Apr-09-20Upgrade Citigroup Neutral → Buy $71 → $67
Feb-20-20Downgrade RBC Capital Mkts Outperform → Sector Perform
Feb-20-20Downgrade Citigroup Buy → Neutral $55 → $71
Nov-12-19Initiated SunTrust Buy $78
May-13-19Upgrade BofA/Merrill Neutral → Buy $43 → $49
Apr-11-19Initiated Bernstein Outperform $48
Oct-03-18Upgrade BofA/Merrill Underperform → Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $66
Jul-19-18Initiated Credit Suisse Outperform $49
Jun-18-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Apr-04-18Downgrade Barclays Equal Weight → Underweight $24 → $26
Sep-13-21 08:00AM  
Aadi Bioscience Appoints Emma Reeve to its Board of Directors
GlobeNewswire
Sep-07-21 08:00AM  
PTC Therapeutics Recognizes 2021 STRIVE Awards Recipients for Initiatives Supporting Duchenne Patient Community
PR Newswire
Aug-27-21 08:00AM  
PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences
PR Newswire +5.25%
Aug-24-21 07:06AM  
PTC Therapeutics' Waylivra Scores Approval In Brazil For Genetic Disorder
Benzinga
Aug-23-21 04:30PM  
PTC Therapeutics Announces Waylivra Approval in Brazil as First Treatment for Familial Chylomicronemia Syndrome
PR Newswire
09:00AM  
Targeting the Putamen with Gene Therapy Leads to Sustained Improvements in Motor and Non-Motor Functions in Children with AADC Deficiency
PR Newswire
Aug-20-21 04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
Aug-10-21 04:34AM  
Investing in Therapeutics (NASDAQ:PTCT) five years ago would have delivered you a 385% gain
Simply Wall St.
Jul-29-21 04:00PM  
PTC Therapeutics Provides a Corporate Update and Reports Second Quarter 2021 Financial Results
PR Newswire
Jul-28-21 05:00PM  
Significant Improvements in Survival and Developmental Milestones Demonstrated in Type 1 SMA Patients Treated with Evrysdi
PR Newswire
Jul-22-21 03:03PM  
PTC Therapeutics (PTCT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Zacks
Jul-19-21 12:58PM  
Do Hedge Funds Love PTC Therapeutics, Inc. (PTCT)?
Insider Monkey
Jul-15-21 08:00AM  
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2021 Financial Results
PR Newswire
Jun-24-21 08:00AM  
Results Add to Body of Evidence Confirming EMFLAZA®'s Benefit Over Prednisone
PR Newswire
Jun-23-21 08:00AM  
Evrysdi Approved in Japan for the Treatment of Spinal Muscular Atrophy
PR Newswire
Jun-15-21 04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
Jun-11-21 07:10AM  
A Look At The Intrinsic Value Of PTC Therapeutics, Inc. (NASDAQ:PTCT)
Simply Wall St.
01:00AM  
Pre-symptomatic Infants with Spinal Muscular Atrophy Achieved Same Motor Milestones as Healthy Children After Treatment with Evrysdi in RAINBOWFISH
PR Newswire
Jun-09-21 08:00AM  
Health and Human Services Expert Mary L. Smith Joins PTC Therapeutics' Board of Directors
PR Newswire
May-27-21 10:23AM  
PTC Therapeutics' (PTCT) PTC923 Gets Orphan Drug Tag in US & EU
Zacks
May-26-21 08:00AM  
PTC Therapeutics Announces Orphan Drug Designations of PTC923 for the Treatment of Hyperphenylalaninemia
PR Newswire
May-19-21 08:00AM  
PTC Therapeutics to Participate at Upcoming Virtual Investor Conference
PR Newswire
May-17-21 08:00AM  
New Data Shows Devastating Impact of AADC Deficiency on Caregivers
PR Newswire
May-04-21 05:25PM  
PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates
Zacks -5.64%
04:01PM  
PTC Therapeutics Provides a Corporate Update and Reports First Quarter 2021 Financial Results
PR Newswire
02:30PM  
PTC Therapeutics, Inc. to Host Earnings Call
ACCESSWIRE
Apr-30-21 06:29AM  
PTC Therapeutics (PTCT) Enters Oversold Territory
Zacks
Apr-27-21 08:00AM  
PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences
PR Newswire
Apr-24-21 05:08PM  
Is PTCT Stock A Buy or Sell?
Insider Monkey
Apr-20-21 08:00AM  
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2021 Financial Results
PR Newswire
Apr-19-21 04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
Apr-15-21 01:00AM  
Continued Improvements in Motor Milestones in Infants with Type 1 Spinal Muscular Atrophy After Two Years of Treatment with Evrysdi
PR Newswire
Apr-14-21 08:00AM  
PTC Therapeutics Launches the PTC Pinpoint Direct Program for Patient-Initiated Genetic Testing
PR Newswire
Apr-12-21 07:35AM  
Is Therapeutics (NASDAQ:PTCT) Using Debt In A Risky Way?
Simply Wall St.
Apr-07-21 09:30AM  
PTC Therapeutics Received Gallup's "Don Clifton Strengths-Based Culture" Award
PR Newswire
08:50AM  
PTC Therapeutics to Host PTC518 Huntington Disease Deep Dive Webinar
PR Newswire
Apr-01-21 08:00AM  
PTC Therapeutics Announces Commercial Milestone Payment Following the Recent European Approval of Evrysdi
PR Newswire
Mar-30-21 07:05AM  
PTC Therapeutics-Roche's Evrysdi Approved In Europe For Muscular Atrophy
Benzinga
01:00AM  
PTC Therapeutics Announces the European Approval of Evrysdi for the Treatment of Spinal Muscular Atrophy
PR Newswire
Mar-16-21 02:00AM  
Results from the Second Year of Evrysdi (risdiplam) Treatment Demonstrated Sustained Improvement of Motor Function in a Broad Range of SMA Patients
PR Newswire
Mar-15-21 08:00AM  
PTC Presents Results from a Real-World Study of Steroid Switching in the Treatment of Patients with Dystrophinopathies
PR Newswire
Mar-09-21 08:00AM  
Spinal Muscular Atrophy (SMA) Foundation and PTC Therapeutics Expand Partnership to Advance Drug Discovery and Development Research in Regenerative Medicine
PR Newswire
Feb-26-21 06:40AM  
CHMP Adopts Positive Opinion for Evrysdi for the Treatment of Spinal Muscular Atrophy in Adults and Children Aged Two Months and Older
PR Newswire
Feb-25-21 07:10PM  
PTC Therapeutics (PTCT) Reports Q4 Loss, Tops Revenue Estimates
Zacks
02:30PM  
PTC Therapeutics, Inc. to Host Earnings Call
ACCESSWIRE
Feb-24-21 05:08PM  
Positive Data from FIREFISH Study of Evrysdi (risdiplam) in Infants with Type 1 Spinal Muscular Atrophy Published in The New England Journal of Medicine
PR Newswire
Feb-17-21 08:00AM  
PTC Therapeutics Reports the Initiation of the Second Stage of the FITE19 Phase 2/3 Clinical Trial Evaluating PTC299 for the Treatment of COVID-19
PR Newswire
Feb-16-21 08:00AM  
PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences
PR Newswire
Feb-15-21 04:09AM  
Loss-Making PTC Therapeutics, Inc. (NASDAQ:PTCT) Expected To Breakeven In The Medium-Term
Simply Wall St.
Feb-11-21 08:00AM  
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results
PR Newswire
Feb-04-21 04:01PM  
PTC Therapeutics to Host Call to Review Results from its Study of Translarna (ataluren) in Patients with Nonsense Mutation Duchenne Muscular Dystrophy
PR Newswire
Jan-14-21 08:00AM  
PTC Therapeutics Opens Applications for the Annual STRIVE Awards Program and Introduces a New Award Category
PR Newswire
Jan-13-21 04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
Jan-11-21 06:30AM  
PTC Therapeutics Provides Update on R&D Pipeline and Commercial Progress at 39th Annual J.P. Morgan Healthcare Conference
PR Newswire
Jan-04-21 08:00AM  
PTC Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
PR Newswire
Dec-31-20 02:57AM  
Can You Imagine How Jubilant Therapeutics' (NASDAQ:PTCT) Shareholders Feel About Its 239% Share Price Gain?
Simply Wall St.
Dec-18-20 04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
Dec-09-20 08:00AM  
PTC Therapeutics to Host Translarna Deep Dive Webinar
PR Newswire
Dec-04-20 04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
08:00AM  
PTC Announces Translarna Approval in Russia for the Treatment of Duchenne Muscular Dystrophy
PR Newswire
Nov-30-20 08:00AM  
PTC Therapeutics Announces Initiation of Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich Ataxia
PR Newswire
Nov-25-20 03:01AM  
Here's What We Think About Therapeutics' (NASDAQ:PTCT) CEO Pay
Simply Wall St.
Nov-19-20 08:00AM  
PTC Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Conference
PR Newswire
Nov-18-20 08:00AM  
PTC Therapeutics Announces Key Regulatory Designations for PTC596 to Advance Treatment of Two Rare Oncology Indications
PR Newswire
Nov-17-20 08:00AM  
PTC Therapeutics Announces that PTC518 Has Entered into a Phase 1 Clinical Trial for the Huntington's Disease Program
PR Newswire
Nov-16-20 08:00AM  
PTC Therapeutics Highlights Data on High Disease Burden and Value of Treatment Across Two Rare Diseases
PR Newswire
Oct-29-20 05:35PM  
PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates
Zacks
04:01PM  
PTC Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
PR Newswire
02:30PM  
PTC Therapeutics, Inc.to Host Earnings Call
ACCESSWIRE
Oct-28-20 04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
08:00AM  
PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences
PR Newswire
Oct-26-20 08:00AM  
PTC Therapeutics Announces Initiation of a Registration-Directed Clinical Trial to Evaluate Vatiquinone in Mitochondrial Epilepsy
PR Newswire
Oct-22-20 12:34PM  
Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for
Zacks
08:00AM  
PTC Therapeutics and AADC Family Network Announce First-Ever AADC Deficiency Awareness Day in Massachusetts
PR Newswire
Oct-21-20 08:33AM  
Evrysdi (risdiplam) Continues to Make Global Progress for the Treatment of Spinal Muscular Atrophy
PR Newswire
Oct-20-20 12:58PM  
Is Therapeutics (NASDAQ:PTCT) Using Debt In A Risky Way?
Simply Wall St.
Oct-15-20 08:00AM  
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2020 Financial Results
PR Newswire
Sep-28-20 01:00AM  
Two-Year Data of Evrysdi (risdiplam) in Infants with Spinal Muscular Atrophy Demonstrate Continued Improvement of Developmental Milestones
PR Newswire
Sep-25-20 04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
Sep-24-20 08:00AM  
PTC Therapeutics to Present at the Jefferies Virtual Gene Therapy/Editing Summit
PR Newswire
Sep-15-20 11:02AM  
Hedge Funds Are Dipping Their Toes Back Into PTC Therapeutics, Inc. (PTCT)
Insider Monkey
Sep-14-20 03:20PM  
Should You Take Comfort From Insider Transactions At PTC Therapeutics, Inc. (NASDAQ:PTCT)?
Simply Wall St. +6.84%
Sep-09-20 08:00AM  
PTC Therapeutics Launches PTC PINPOINT - A Genetic Testing Program for Individuals Suspected of Having Neurotransmitter Disorders
PR Newswire
Sep-08-20 08:00AM  
PTC Therapeutics' 2020 STRIVE Awards for Duchenne Muscular Dystrophy Recognize Four Patient Advocacy Organizations
PR Newswire
Sep-03-20 08:00AM  
PTC Therapeutics to Present at the Cantor Virtual Global Healthcare Conference
PR Newswire
Aug-27-20 09:39AM  
PTC Therapeutics Gets First Milestone Payment for SMA Drug
Zacks
Aug-26-20 09:44AM  
PTC reports first milestone payment from Roche for spinal muscular atrophy drug
MarketWatch
08:00AM  
PTC Therapeutics Announces First Commercial Milestone Payment Following U.S. FDA Approval of Evrysdi (risdiplam)
PR Newswire
Aug-21-20 04:30PM  
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
Aug-18-20 05:07PM  
PTC Therapeutics' Application for SMA Drug Accepted by EU
Zacks
Aug-17-20 08:00AM  
PTC Announces the Acceptance of the European Marketing Authorization Application for Evrysdi (risdiplam) for the Treatment of Spinal Muscular Atrophy
PR Newswire
Aug-10-20 07:07AM  
PTC Therapeutics Scores Early FDA Nod For Evrysdi; Analyst Stays Sidelined
SmarterAnalyst
Aug-08-20 10:40AM  
FDA approves Roche's new spinal muscular atrophy drug
MarketWatch
Aug-07-20 02:46PM  
PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Path To Profitability
Simply Wall St.
01:54PM  
PTC Therapeutics Announces FDA Approval of Evrysdi (risdiplam) for the Treatment of Spinal Muscular Atrophy in Adults and Children 2 months and older
PR Newswire
Aug-06-20 08:00AM  
PTC Therapeutics' Mary Frances Harmon Named One of the Most Inspiring Leaders in Life Sciences by PharmaVOICE Magazine
PR Newswire
Aug-05-20 06:15PM  
PTC Therapeutics (PTCT) Reports Q2 Loss, Lags Revenue Estimates
Zacks
04:01PM  
PTC Therapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate Update
PR Newswire
Jul-29-20 12:33PM  
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Should You Buy?
Zacks
Jul-22-20 08:00AM  
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2020 Financial Results
PR Newswire
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, including rare diseases and oncology. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of SMA in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Boulding Mark ElliottExec. VP and CLOSep 02Option Exercise18.013,36360,56851,737Sep 03 04:06 PM
Boulding Mark ElliottExec. VP and CLOSep 02Sale45.013,363151,37548,374Sep 03 04:06 PM
Okey StephanieDirectorAug 13Sale40.061,65066,094963Aug 17 04:04 PM
Boulding Mark ElliottExec. VP and CLOJul 09Option Exercise18.011,42925,73648,922Jul 12 04:26 PM
Boulding Mark ElliottExec. VP and CLOJul 09Sale45.001,42964,30648,374Jul 12 04:26 PM
Boulding Mark ElliottExec. VP and CLOJul 08Option Exercise16.277,805127,00850,174Jul 12 04:26 PM
Boulding Mark ElliottExec. VP and CLOJul 08Sale45.227,805352,96848,374Jul 12 04:26 PM
Svoronos DawnDirectorJun 09Sale41.8836515,28827,065Jun 11 04:47 PM
Klein Matthew B.Chief Development OfficerApr 20Sale46.741,64176,70416,809Apr 21 04:09 PM
Klein Matthew B.Chief Development OfficerApr 19Sale48.1785941,37618,450Apr 21 04:09 PM
Pauwels EricChief Business OfficerApr 19Sale48.1778637,86035,701Apr 21 04:12 PM
Utter Christine MarieSVP, Finance & CAOFeb 08Option Exercise33.022,65787,73419,166Feb 10 04:24 PM
Utter Christine MarieSVP, Finance & CAOFeb 08Sale66.002,657175,36216,509Feb 10 04:24 PM
Utter Christine MarieSVP, Finance & CAOFeb 02Sale57.6465237,58116,509Feb 03 07:46 AM
Utter Christine MarieSVP, Finance & CAOFeb 01Sale56.9636820,96017,161Feb 03 07:46 AM
Hill Emily LuisaChief Financial OfficerFeb 01Sale56.9654130,81323,306Feb 02 06:24 PM
Boulding Mark ElliottExec. VP and CLOFeb 01Sale56.9677844,31248,374Feb 02 06:23 PM
Almstead Neil GregoryChief Technical Ops OfficerFeb 01Sale56.96281,5951,819Feb 02 06:22 PM
Almstead Neil GregoryChief Technical Ops OfficerFeb 01Sale56.9697355,41835,814Feb 02 06:22 PM
Pauwels EricChief Business OfficerFeb 01Sale56.9636220,61836,487Feb 02 06:21 PM
Peltz Stuart WalterChief Executive OfficerFeb 01Sale56.9628316,11915,081Feb 02 06:19 PM
Peltz Stuart WalterChief Executive OfficerFeb 01Sale56.961,968112,08980,315Feb 02 06:19 PM
Svoronos DawnDirectorFeb 01Sale56.9650628,82027,430Feb 02 06:18 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 25Sale63.1554134,1661,847Jan 27 04:26 PM
Hill Emily LuisaChief Financial OfficerJan 25Sale62.0527517,06523,847Jan 27 04:25 PM
Pauwels EricChief Business OfficerJan 25Sale62.0543126,74536,849Jan 27 04:24 PM
Peltz Stuart WalterChief Executive OfficerJan 25Sale62.0535021,71915,364Jan 27 04:23 PM
Klein Matthew B.Chief Development OfficerJan 15Option Exercise38.984,300167,61423,609Jan 20 04:10 PM
Klein Matthew B.Chief Development OfficerJan 15Sale69.094,300297,07819,309Jan 20 04:10 PM
Utter Christine MarieSVP, Finance & CAOJan 13Option Exercise16.393,28853,87420,029Jan 15 04:04 PM
Utter Christine MarieSVP, Finance & CAOJan 13Sale66.573,947262,75217,529Jan 15 04:04 PM
Hill Emily LuisaChief Financial OfficerJan 08Option Exercise23.5626,033613,40934,622Jan 12 04:15 PM
Klein Matthew B.Chief Development OfficerJan 08Option Exercise38.985,500214,39024,809Jan 12 04:17 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 08Option Exercise27.051,30035,1653,688Jan 12 04:18 PM
Klein Matthew B.Chief Development OfficerJan 08Sale69.715,500383,41019,309Jan 12 04:17 PM
Hill Emily LuisaChief Financial OfficerJan 08Sale69.7526,0331,815,80224,122Jan 12 04:15 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 08Sale69.001,30089,7002,388Jan 12 04:18 PM
Klein Matthew B.Chief Development OfficerJan 07Option Exercise38.983,886151,47623,195Jan 08 05:12 PM
Klein Matthew B.Chief Development OfficerJan 07Sale68.983,886268,05619,309Jan 08 05:12 PM
Boulding Mark ElliottExec. VP and CLOJan 05Sale62.3777248,15038,952Jan 07 05:05 PM
Hill Emily LuisaChief Financial OfficerJan 05Sale62.3728817,96313,322Jan 07 05:02 PM
Pauwels EricChief Business OfficerJan 05Sale62.371,06766,54927,080Jan 07 04:59 PM
Peltz Stuart WalterChief Executive OfficerJan 05Sale62.3766641,53811,754Jan 07 04:57 PM
Peltz Stuart WalterChief Executive OfficerJan 05Sale62.371,40287,44354,683Jan 07 04:57 PM
Utter Christine MarieSVP, Finance & CAOJan 05Sale62.3731619,7099,488Jan 07 04:55 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 05Sale62.371247,7341,788Jan 07 04:54 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 05Sale62.3750231,31026,587Jan 07 04:54 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 04Option Exercise10.856006,5102,512Jan 06 04:06 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 04Option Exercise20.79103,4382,150,35975,214Jan 06 04:06 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 04Sale60.6560036,3901,912Jan 06 04:06 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 04Sale60.58103,4386,266,16727,089Jan 06 04:06 PM
Peltz Stuart WalterChief Executive OfficerDec 30Option Exercise31.74285,7189,067,681225,866Dec 31 04:06 PM
Peltz Stuart WalterChief Executive OfficerDec 30Sale61.74285,71817,641,45956,085Dec 31 04:06 PM
Reeve EmmaDirectorDec 15Option Exercise33.021,02833,9452,678Dec 16 04:09 PM
Reeve EmmaDirectorDec 14Option Exercise33.021,97265,1152,650Dec 16 04:09 PM
Reeve EmmaDirectorDec 14Sale68.001,972134,0961,650Dec 16 04:09 PM
Okey StephanieDirectorDec 08Sale62.5268742,954963Dec 10 04:09 PM
Peltz Stuart WalterChief Executive OfficerDec 07Option Exercise16.6820,017333,95463,675Dec 09 07:52 PM
Peltz Stuart WalterChief Executive OfficerDec 07Option Exercise22.66348,4177,894,942248,877Dec 09 07:54 PM
Peltz Stuart WalterChief Executive OfficerDec 07Sale61.4220,0171,229,48456,085Dec 09 07:52 PM
Peltz Stuart WalterChief Executive OfficerDec 07Sale61.00348,41721,254,76656,085Dec 09 07:54 PM
Almstead Neil GregoryChief Technical Ops OfficerNov 04Option Exercise11.2324,062270,21648,964Nov 06 04:27 PM
Jacobson Allan StevenDirectorNov 04Option Exercise10.8520,000217,00023,498Nov 06 04:30 PM
Utter Christine MarieSVP, Finance & CAONov 04Option Exercise30.9731,758983,52620,187Nov 06 04:35 PM
Peltz Stuart WalterChief Executive OfficerNov 04Option Exercise25.3838,328972,95520,599Nov 06 04:40 PM
Utter Christine MarieSVP, Finance & CAONov 04Sale60.0631,7581,907,4049,562Nov 06 04:35 PM
Peltz Stuart WalterChief Executive OfficerNov 04Sale60.0049,3652,961,90012,178Nov 06 04:40 PM
Jacobson Allan StevenDirectorNov 04Sale60.0020,0001,200,0003,498Nov 06 04:30 PM
Almstead Neil GregoryChief Technical Ops OfficerNov 04Sale60.0024,0621,443,72027,089Nov 06 04:27 PM
Pauwels EricChief Business OfficerNov 03Sale56.506,194349,96127,647Nov 05 04:25 PM
Peltz Stuart WalterChief Executive OfficerNov 02Option Exercise10.8550,000542,500106,085Nov 03 07:52 PM
Peltz Stuart WalterChief Executive OfficerNov 02Sale53.6650,0002,682,95456,085Nov 03 07:52 PM
SOUTHWELL DAVID PDirectorOct 16Option Exercise11.0227,000297,51016,650Oct 20 04:34 PM
Jacobson Allan StevenDirectorOct 16Sale51.295,000256,4503,498Oct 20 04:35 PM
SOUTHWELL DAVID PDirectorOct 16Sale51.5427,0001,391,5441,650Oct 20 04:34 PM
Peltz Stuart WalterChief Executive OfficerOct 07Option Exercise11.1171,104789,785104,260Oct 09 04:20 PM
Peltz Stuart WalterChief Executive OfficerOct 07Sale53.3871,1043,795,26256,085Oct 09 04:20 PM
Utter Christine MarieSVP, Finance & CAOOct 06Option Exercise18.012,50045,02512,062Oct 07 08:59 PM
Peltz Stuart WalterChief Executive OfficerOct 06Option Exercise11.01124,3511,368,902107,910Oct 07 09:01 PM
Peltz Stuart WalterChief Executive OfficerOct 06Sale50.12124,3516,233,08356,085Oct 07 09:01 PM
Utter Christine MarieSVP, Finance & CAOOct 06Sale50.082,500125,2089,562Oct 07 08:59 PM
Utter Christine MarieSVP, Finance & CAOOct 05Option Exercise11.237878,83810,349Oct 07 08:59 PM
Peltz Stuart WalterChief Executive OfficerOct 05Option Exercise10.8555,460601,741110,645Oct 07 09:01 PM
Peltz Stuart WalterChief Executive OfficerOct 05Sale50.0055,4602,773,00056,085Oct 07 09:01 PM
Utter Christine MarieSVP, Finance & CAOOct 05Sale48.6878738,3119,562Oct 07 08:59 PM
open in yahoo | open in reuters | open in marketwatch | open in google
affiliate • advertise • contact • privacy • help
Do not sell my personal information
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2021 FINVIZ.com. All Rights Reserved.